David A. Siegel Collegium Pharmaceutical, Inc Transaction History

Two Sigma Advisers, LP

$42.8 Billion
Q1 2025

A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Collegium Pharmaceutical, Inc stock. As of the latest transaction made, Two Sigma Advisers, LP holds 46,300 shares of COLL stock, worth $1.37 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

46,300

Previous 72,000 35.69%

Holding current value

$1.37 Million

Previous $2.06 Million 32.98%

% of portfolio

0.0%

Previous 0.0%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 15, 2025	SELL	$28.04 - $33.91 $720,628 - $871,486	-25,700 Reduced 35.69%	46,300 $1.38 Million
Q4 2024 Feb 14, 2025	SELL	$28.61 - $41.86 $4.16 Million - $6.08 Million	-145,300 Reduced 66.87%	72,000 $2.06 Million
Q3 2024 Nov 14, 2024	SELL	$31.4 - $39.07 $1.27 Million - $1.59 Million	-40,600 Reduced 15.74%	217,300 $8.4 Million
Q2 2024 Aug 14, 2024	SELL	$31.36 - $39.99 $307,328 - $391,902	-9,800 Reduced 3.66%	257,900 $8.3 Million
Q1 2024 May 15, 2024	BUY	$31.23 - $40.91 $708,921 - $928,656	22,700 Added 9.27%	267,700 $10.4 Million
Q4 2023 Feb 14, 2024	SELL	$21.16 - $30.8 $1.35 Million - $1.97 Million	-64,000 Reduced 20.71%	245,000 $7.54 Million
Q3 2023 Nov 14, 2023	SELL	$21.23 - $24.28 $12,738 - $14,568	-600 Reduced 0.19%	309,000 $6.91 Million
Q2 2023 Aug 14, 2023	BUY	$21.06 - $24.0 $2.79 Million - $3.18 Million	132,600 Added 74.92%	309,600 $6.65 Million
Q1 2023 May 15, 2023	BUY	$23.0 - $29.88 $3.09 Million - $4.02 Million	134,500 Added 316.47%	177,000 $4.25 Million
Q4 2022 Feb 14, 2023	BUY	$16.14 - $23.55 $472,902 - $690,015	29,300 Added 221.97%	42,500 $986,000
Q3 2022 Nov 14, 2022	BUY	$15.46 - $20.1 $204,072 - $265,320	13,200 New	13,200 $211,000
Q2 2022 Aug 15, 2022	SELL	$14.22 - $20.88 $379,674 - $557,496	-26,700 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$17.2 - $22.5 $86,000 - $112,500	5,000 Added 23.04%	26,700 $544,000
Q4 2021 Feb 14, 2022	SELL	$17.5 - $21.35 $138,250 - $168,665	-7,900 Reduced 26.69%	21,700 $405,000
Q3 2021 Nov 15, 2021	SELL	$17.75 - $25.39 $481,025 - $688,069	-27,100 Reduced 47.8%	29,600 $584,000
Q2 2021 Aug 16, 2021	SELL	$21.74 - $25.28 $626,112 - $728,064	-28,800 Reduced 33.68%	56,700 $1.34 Million
Q1 2021 May 17, 2021	BUY	$19.25 - $26.1 $1.65 Million - $2.23 Million	85,500 New	85,500 $2.03 Million
Q4 2020 Feb 16, 2021	SELL	$17.83 - $22.29 $821,962 - $1.03 Million	-46,100 Closed	0 $0
Q3 2020 Nov 16, 2020	SELL	$15.78 - $20.82 $1.02 Million - $1.34 Million	-64,600 Reduced 58.36%	46,100 $960,000
Q2 2020 Aug 14, 2020	BUY	$15.49 - $23.51 $472,445 - $717,055	30,500 Added 38.03%	110,700 $1.94 Million
Q1 2020 May 15, 2020	BUY	$13.89 - $25.45 $798,675 - $1.46 Million	57,500 Added 253.3%	80,200 $1.31 Million
Q4 2019 Feb 14, 2020	BUY	$10.7 - $22.24 $242,889 - $504,847	22,700 New	22,700 $467,000
Q3 2019 Nov 14, 2019	SELL	$10.16 - $13.28 $294,640 - $385,120	-29,000 Closed	0 $0
Q2 2019 Aug 14, 2019	BUY	$10.62 - $16.59 $20,178 - $31,521	1,900 Added 7.01%	29,000 $381,000
Q1 2019 May 15, 2019	BUY	$13.58 - $18.72 $58,394 - $80,496	4,300 Added 18.86%	27,100 $410,000
Q4 2018 Feb 14, 2019	SELL	$14.78 - $19.68 $121,196 - $161,376	-8,200 Reduced 26.45%	22,800 $391,000
Q3 2018 Nov 14, 2018	BUY	$14.16 - $24.3 $226,560 - $388,800	16,000 Added 106.67%	31,000 $457,000
Q2 2018 Aug 14, 2018	BUY	$21.79 - $28.29 $326,850 - $424,350	15,000 New	15,000 $358,000

Others Institutions Holding COLL

# of Institutions

254

Shares Held

37.2M

Call Options Held

61.1K

Put Options Held

5.8K

View Full List

About COLLEGIUM PHARMACEUTICAL, INC

Ticker COLL
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 34,126,200
Market Cap $1.01B
Description
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and commercializes medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol; and Xtampza ...

More about COLL

Track David A. Siegel's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.

Account